| CP-690550 |
| 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile |
| (CAS 477600-75-2) |
 |
| Description： |
Tofacitinib (trade names Xeljanz and Jakvinus, formerly tasocitinib,[1] CP-690550[2]) is a drug of the janus kinase (JAK) inhibitor class, discovered and developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and Russia, and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection.
|
| Product No. |
KT00297 |
| Product Name |
CP-690550 |
| Synonyms |
Tofacitinib |
| Formal Name |
3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile |
| CAS Number |
477600-75-2 |
| Molecular Formula |
C16H20N6O |
| Formula Weight |
312.37 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
(3R,4S)-Tofacitinib
(3S,4R)-Tofacitinib
(3S,4S)-Tofacitinib
AG-490
AT9283
AZD-1480
BMS-911543
CEP-33779
CYT387
GLPG0634
|
|
